(Reuters) -The U.S. Food and Drug Administration approved Soleno Therapeutics’ drug to treat a rare genetic disorder on Wednesday, making it the first treatment available for patients who experience feelings of intense and persistent hunger. Shares of the company were halted for trading. The drug, branded as Vykat XR, received FDA’s approval to treat Prader-Willi syndrome, a genetic disorder
Day: March 26, 2025
EDWARDSVILLE, LUZERNE COUNTY (WBRE/WYOU) — A group of Luzerne County high school students is partnering with a national organization to end book deserts and increase literacy for pre-K students. The goal of the two organizations is to get books into the hands of kids whose families may not be able to afford them. The Pennsylvania Key […]
After the White House argued, repeatedly, that there was no classified information in the chat, The Atlantic published it.
After the White House argued, repeatedly, that there was no classified information in the chat, The Atlantic published it.
Tired of looking tired? Some people are turning to “jelly roll” Botox to fake a full night’s sleep.
“Trump, you may love Michael Waltz. You love Pete Hegseth. You may love these guys. Somebody has to go down,” David Portnoy said.
Bezos and Sánchez are reportedly sparing no expense to ensure their A-list guests are blown away by their Italian wedding.
In September 2024, the Foo Fighters frontman fessed up to cheating and welcoming a baby outside of their union.
The US President say the tariffs will come into effect on 2 April.
The panel said that while further argument was needed, lawyers for the migrants would likely succeed in their claims that the Venezuelans had been denied due process.
